UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

179P Nivolumab monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC) in routine clinical practice in a Spanish center

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S135-S135

2016

Volltextzugriff (PDF)

SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

Clinical & translational oncology, 2022-04, Vol.24 (4), p.635-645

2022

Volltextzugriff (PDF)

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

Clinical & translational oncology, 2018-08, Vol.20 (8), p.1072-1079

2018

Volltextzugriff (PDF)

5PSQ-066 The other side of immunotherapy: safety and toxicity management in clinical practice

European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A231-A232

2019

Volltextzugriff (PDF)

Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients

Annals of oncology, 2018-10, Vol.29, p.viii510-viii510

2018

Volltextzugriff (PDF)

GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii531-viii531

2018

Volltextzugriff (PDF)

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

ESMO open, 2021-10, Vol.6 (5), p.100279-100279, Article 100279

2021

Volltextzugriff (PDF)

Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy

Journal of medical genetics, 2013-09, Vol.50 (9), p.599-605

2013

Volltextzugriff (PDF)

2019P Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential

Annals of oncology, 2023-10, Vol.34, p.S1073-S1073

2023

Volltextzugriff (PDF)

26P Analysis of prognostic and predictive factors of response in squamous cell carcinoma using NGS techniques

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S709-S709

2021

Volltextzugriff (PDF)

P1.21-07 Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S236-S237

2023

Volltextzugriff (PDF)

P1.22-16 ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S252

2023

Volltextzugriff (PDF)

25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2021-12, Vol.32, p.S1384

2021

Volltextzugriff (PDF)

1569P A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF): A comparative analysis

Annals of oncology, 2021-09, Vol.32, p.S1134-S1134

2021

Volltextzugriff (PDF)

P1.12-04 The FLARE score and circulating neutrophils are associated with poor Covid-19 outcomes in patients with thoracic cancers

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S112-S112

2022

Volltextzugriff (PDF)

204P Immune-related adverse events (IrAEs) as a predictor of response to immunotherapy in patients with lung cancer

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S808-S809

2021

Volltextzugriff (PDF)

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

Clinical & translational oncology, 2018-08, Vol.20 (8), p.1096-1096

2018

Volltextzugriff (PDF)

1069P A multicenter phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumours in adulthood (GETHI021)

Annals of oncology, 2020-09, Vol.31, p.S727-S727

2020

Volltextzugriff (PDF)

1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score

Annals of oncology, 2020-09, Vol.31, p.S1008-S1008

2020

Volltextzugriff (PDF)

1681P First results of the COCO study: COVID-19 outcomes in patients with cancer

Annals of oncology, 2020-09, Vol.31, p.S996-S996

2020

Volltextzugriff (PDF)

EP1.06-09 Mesothelial Tumors Registry in Spain: A Retrospective Multicenter Study

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S993-S993

2019

Volltextzugriff (PDF)

P1.01-130 Clinical Experience with Nintedanib in Previously Treated Non-Small Cell Lung Cancer in Spain: A Retrospective Multicenter Study

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S414-S414

2019

Volltextzugriff (PDF)

P2.01-81 Predictive Factors of Survival in Patients Treated with Nintedanib: A Multicenter Retrospective Spanish Study

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S671-S672

2019

Volltextzugriff (PDF)

P2.01-55 Immunotherapy First or After Nintedanib?: A Spanish Experience

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S660-S661

2019

Volltextzugriff (PDF)

1262P - Predictive model for survival in advanced non-small cell lung cancer (NSCLC) treated with frontline pembrolizumab

Annals of oncology, 2019-10, Vol.30, p.v514-v514

2019

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(72)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Humans
(5)
Oncology
(5)
Medicine
(4)
Male
(3)
Medicine & Public Health
(3)
Pulmonary Surfactants - Administration & Dosage
(3)
Respiratory System
(3)
Administration, Inhalation
(2)
Adult
(2)
Aerosol
(2)
Aerosol Production
(2)
Aerosols
(2)
Aged
(2)
Antibodies, Monoclonal - Therapeutic Use
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Biological And Medical Sciences
(2)
Catheters
(2)
Chemotherapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

179P Nivolumab monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC) in routine clinical practice in a Spanish center

SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

5PSQ-066 The other side of immunotherapy: safety and toxicity management in clinical practice

Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients

GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy

2019P Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential

26P Analysis of prognostic and predictive factors of response in squamous cell carcinoma using NGS techniques

P1.21-07 Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer

P1.22-16 ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

1569P A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF): A comparative analysis

P1.12-04 The FLARE score and circulating neutrophils are associated with poor Covid-19 outcomes in patients with thoracic cancers

204P Immune-related adverse events (IrAEs) as a predictor of response to immunotherapy in patients with lung cancer

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

1069P A multicenter phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumours in adulthood (GETHI021)

1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score

1681P First results of the COCO study: COVID-19 outcomes in patients with cancer

EP1.06-09 Mesothelial Tumors Registry in Spain: A Retrospective Multicenter Study

P1.01-130 Clinical Experience with Nintedanib in Previously Treated Non-Small Cell Lung Cancer in Spain: A Retrospective Multicenter Study

P2.01-81 Predictive Factors of Survival in Patients Treated with Nintedanib: A Multicenter Retrospective Spanish Study

P2.01-55 Immunotherapy First or After Nintedanib?: A Spanish Experience

1262P - Predictive model for survival in advanced non-small cell lung cancer (NSCLC) treated with frontline pembrolizumab

Suchergebnisse filtern